Earnings Feed
Start Free
Home/Filings/4/0000950170-25-043935
4//SEC Filing

Patel Sandip I 4

Accession 0000950170-25-043935

CIK 0001541157other
View on SEC.govCompany Profile

Filed

Mar 23, 8:00 PM ET

Accepted

Mar 24, 5:00 PM ET

Size

12.4 KB

Accession

0000950170-25-043935

Insider Transaction Report

Form 4
Period: 2025-03-20
Akari Therapeutics PlcAKTX
Patel Sandip I
Director
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-03-20+225,000→ 225,000 total
    Exercise: $1.50Exp: 2035-03-20→ American Depositary Shares representing Ordinary Shares (225,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2025-03-20+175,000→ 175,000 total
    Exercise: $1.50Exp: 2035-03-20→ American Depositary Shares representing Ordinary Shares (175,000 underlying)
Holdings

  • American Depositary Shares representing Ordinary Shares

    (indirect: By LLC)
    20,219

  • American Depositary Shares representing Ordinary Shares

    451,857

  • American Depositary Shares representing Ordinary Shares

    (indirect: By LLC)
    6,250

  • American Depositary Shares representing Ordinary Shares

    (indirect: By LLC)
    13,901

  • American Depositary Shares representing Ordinary Shares

    (indirect: By LLC)
    19,880
Footnotes (3)
  • [F1]Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
  • [F2]The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer.
  • [F3]The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter.

Documents

1 file

Issuer

Akari Therapeutics Plc

CIK 0001541157

→
Entity typeother

Related Parties

1
  • filerCIK 0001843601

Filing Metadata

Form type
4
Filed
Mar 23, 8:00 PM ET
Accepted
Mar 24, 5:00 PM ET
Size
12.4 KB
View on SEC.gov